FREE-001

About Freedom Biosciences

Freedom Biosciences is a private, preclinical-stage biotech founded in 2021, headquartered in Boston, USA. The company is built upon the pioneering ketamine research of its co-founder, Dr. John Krystal, and aims to develop next-generation, ketamine-based and combination neuropsychiatric drugs. Its pipeline includes programs targeting treatment-resistant depression and comorbid conditions, with a core strategy of improving upon the first-generation therapies like esketamine. The company is led by CEO Dina Burkitbayeva and combines deep scientific expertise with venture investment experience in the psychedelics sector.

Therapeutic Areas